Despite the fact that unknown results exist with regards to LAG-3 clinical studies, their rationale is founded on the data that suggest the co-targeting of LAG-3 as a promising strategy in order to improve the responses of immunotherapy in several human tumor types. Here, LAG3 is linked to neoplasm.